Clinical study of renal impairment in patients with propylthiouracil-induced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis

Cao,Xiaozhi; Lin,Weiyuan

doi:10.3892/etm.2013.1065

Clinical study of renal impairment in patients with propylthiouracil-induced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis

Authors:
- Xiaozhi Cao
- Weiyuan Lin
View Affiliations

Affiliations: Department of Cardiology, Fuzhou General Hospital, Nanjing Command, PLA, Fuzhou 350025, P.R. China, Renal Department of Internal Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, P.R. China
Published online on: April 15, 2013 https://doi.org/10.3892/etm.2013.1065
Pages: 1619-1622

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to compare renal impairment in patients with propylthiouracil (PTU)‑induced small-vessel vasculitis and patients with primary anti-neutrophil cytoplasmic antibody (ANCA)-induced small-vessel vasculitis. The study compared the pathology and clinical conditions of 10 patients with PTU-associated small-vessel vasculitis and 18 patients with primary ANCA-associated small-vessel vasculitis. All patients showed manifestations of renal impairment. Compared with the primary ANCA‑induced small-vessel vasculitis, patients with PTU‑induced small-vessel vasculitis were mostly female (P<0.05) and deleloped the disease at a younger age (P<0.05). They had a higher positive rate of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA; P<0.05), lower 24 h proteinuria content, lower serum creatinine (P<0.05) and milder histopathological lesions (P<0.05). A number of them had gross hematuria (P<0.05). They rarely used hormone and cytotoxic drugs (P<0.05) during treatment and had a better prognosis (P<0.05). In conclusion, PTU‑induced small-vessel vasculitis has a milder pathology and clinical manifestations with a better prognosis.

View Figures

View References

1.	Erwig LP and Savage CO: ANCA-associated vasculitides: advances in pathophysiology and treatment. Neth J Med. 68:62–67. 2010.PubMed/NCBI
2.	Bosch X, Guilabert A, Espinosa G and Mirapeix E: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 298:655–669. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Santana AN, Woronik V, Halpern AS and Barbas CS: Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update. J Bras Pneumol. 37:809–816. 2011.PubMed/NCBI
4.	Bosch X, Guilabert A and Font J: Antineutrophil cytoplasmic antibodies. Lancet. 368:404–418. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Ghosh S, Bhattacharya M and Dhar S: Churg-strauss syndrome. Indian J Dermatol. 56:718–721. 2011. View Article : Google Scholar
6.	Pagnoux C and Guillevin L: Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol. 22:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Abril A: Churg-strauss syndrome: an update. Curr Rheumatol Rep. 13:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Cooper DS: Antithyroid drugs. N Engl J Med. 352:905–917. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Azizi F: The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 5:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Radić M, Martinović Kaliterna D and Radić J: Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 70:12–17. 2012.
11.	Reinhold-Keller E: Diagnostics and therapy of antineutrophil cytoplasmic antibody (ANCA) associated vasculitides. Curr Pharm Des. 18:4537–4541. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Yu F, Chen M, Gao Y, et al: Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis. 49:607–614. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Sanchez AP and Ward DM: Therapeutic apheresis for renal disorders. Semin Dial. 25:119–131
14.	Stankus SJ and Johnson NT: Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest. 102:1595–1596. 1992. View Article : Google Scholar : PubMed/NCBI
15.	Gao Y and Zhao MH: Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 14:33–41. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Chen M, Gao Y, Guo XH and Zhao MH: Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol. 8:476–483. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Pavone L, Grasselli C, Chierici E, et al: Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol. 33:1299–1306. 2006.PubMed/NCBI
18.	van Timmeren MM and Heeringa P: Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol. 24:8–14. 2012.PubMed/NCBI
19.	Rutgers A and Kallenberg CG: Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol. 24:245–251. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Aras G: Recent aspects of vasculitis and future direction. Intern Med. 50:1869–1877. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Kettritz R: How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol. 169:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
22.	de Lind, van Wijngaarden RA, Hauer HA, Wolterbeek R, et al: Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 17:2264–2274. 2006.PubMed/NCBI